Precision oncology: separating the wheat from the chaff
Open Access
Abstract
Precision oncology based on next-generation sequencing (NGS) test is growing in daily clinical practice. However, the real impact of this strategy in patients’ outcome on a large scale remains uncertain. In this review, we summarise existing literature on this topic, limitations for broad NGS implementation, bottlenecks in genomic variant interpretation and the role of molecular tumour boards.Keywords
This publication has 85 references indexed in Scilit:
- Discovery and saturation analysis of cancer genes across 21 tumour typesNature, 2014
- Mutational heterogeneity in cancer and the search for new cancer-associated genesNature, 2013
- Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center InitiativeClinical Cancer Research, 2012
- Routine Multiplex Mutational Profiling of Melanomas Enables Enrollment in Genotype-Driven Therapeutic TrialsPLOS ONE, 2012
- Intra-tumour heterogeneity: a looking glass for cancer?Nature Reviews Cancer, 2012
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialThe Lancet Oncology, 2012
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaNew England Journal of Medicine, 2009
- Oncogene AddictionCancer Research, 2008
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsNew England Journal of Medicine, 2002